BR112019009925A2 - método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . - Google Patents
método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .Info
- Publication number
- BR112019009925A2 BR112019009925A2 BR112019009925A BR112019009925A BR112019009925A2 BR 112019009925 A2 BR112019009925 A2 BR 112019009925A2 BR 112019009925 A BR112019009925 A BR 112019009925A BR 112019009925 A BR112019009925 A BR 112019009925A BR 112019009925 A2 BR112019009925 A2 BR 112019009925A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treating
- adoptive
- preparing
- infiltrating lymphocytes
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title abstract 2
- 238000002659 cell therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Abstract
em algumas modalidades, são descritos métodos de distribuir uma quantidade terapeuticamente eficaz de um número expandido de linfócitos infiltrantes de tumor obtidos a partir de remanescentes tumorais para um paciente em necessidade do mesmo, para o tratamento de um câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423750P | 2016-11-17 | 2016-11-17 | |
US201762460441P | 2017-02-17 | 2017-02-17 | |
PCT/US2017/062219 WO2018094167A1 (en) | 2016-11-17 | 2017-11-17 | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019009925A2 true BR112019009925A2 (pt) | 2019-10-08 |
Family
ID=60766134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019009925A BR112019009925A2 (pt) | 2016-11-17 | 2017-11-17 | método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . |
Country Status (13)
Country | Link |
---|---|
US (4) | US11401507B2 (pt) |
EP (1) | EP3541930A1 (pt) |
JP (2) | JP7125392B2 (pt) |
KR (1) | KR102618948B1 (pt) |
CN (1) | CN110199016A (pt) |
AU (1) | AU2017362418A1 (pt) |
BR (1) | BR112019009925A2 (pt) |
CA (1) | CA3044250A1 (pt) |
IL (1) | IL266655A (pt) |
MA (1) | MA46916A (pt) |
MX (1) | MX2019005617A (pt) |
TW (1) | TWI826360B (pt) |
WO (1) | WO2018094167A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
WO2018081473A1 (en) * | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI826360B (zh) | 2016-11-17 | 2023-12-21 | 美商艾歐凡斯生物治療公司 | 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法 |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY |
BR112021003678A2 (pt) * | 2018-09-20 | 2021-05-18 | Iovance Biotherapeutics, Inc. | métodos para criopreservar tecido de tumor, para fabricar, para preparar e para expandir linfócitos infiltrantes de tumor, para tratar um indivíduo com câncer e para tratar câncer para um indivíduo humano, e, fragmento de tumor criopreservado . |
KR20210091212A (ko) * | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | 항-pd-1 항체에 불응성인 nsclc 환자의 치료 |
GB201818243D0 (en) * | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
US20220112557A1 (en) * | 2019-01-10 | 2022-04-14 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
CN110938594A (zh) * | 2019-09-12 | 2020-03-31 | 夏建川 | 一种功能增强型til细胞的培养方法 |
MX2022007598A (es) | 2019-12-20 | 2022-09-23 | Instil Bio Uk Ltd | Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos. |
CA3176654A1 (en) | 2020-04-28 | 2021-11-04 | Karl PEGGS | T cell therapy |
CN111705051A (zh) * | 2020-07-28 | 2020-09-25 | 金紫晶(南京)生物医药技术有限公司 | 一种复合消化酶及复合消化酶冻干粉 |
TW202237822A (zh) * | 2020-11-19 | 2022-10-01 | 大陸商蘇州沙礫生物科技有限公司 | 腫瘤浸潤淋巴細胞的培養方法及其用途 |
CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
WO2022166947A1 (zh) * | 2021-02-08 | 2022-08-11 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的制备方法及其用途 |
WO2022204564A2 (en) | 2021-03-25 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
CA3216691A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Culture of tumor infiltrating lymphocytes from tumor digest |
WO2022269250A1 (en) | 2021-06-22 | 2022-12-29 | Achilles Therapeutics Uk Limited | A method for producing antigen-specific t cells |
CN113244389B (zh) * | 2021-07-06 | 2021-09-17 | 诺赛联合(北京)生物医学科技有限公司 | 一种TILs细胞制备方法及在肿瘤治疗的用途 |
CN113755529B (zh) * | 2021-09-15 | 2022-09-23 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种肿瘤增强型肿瘤浸润淋巴细胞的制备方法 |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3201325A (en) | 1963-02-15 | 1965-08-17 | Miles Lab | Process for the recovery of collagenase |
US3705083A (en) | 1966-07-08 | 1972-12-05 | Agricultural Biolog Corp | Process for producing collagenase |
US3821364A (en) | 1966-07-08 | 1974-06-28 | Advance Biofactures Corp | Process of producing collagenase |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8504025D0 (en) | 1985-02-16 | 1985-03-20 | Biopharm Ltd | Hyaluronidase |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
EP0449968B1 (en) | 1988-12-23 | 1999-02-24 | Genentech, Inc. | Process for the preparation of human dnase |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5177017A (en) | 1990-03-22 | 1993-01-05 | Trigen, Inc. | Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum |
US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
US5593877A (en) | 1993-03-11 | 1997-01-14 | The Rockefeller University | Nucleic acid and recombinant production of vespid venom hyaluronidase |
US5422261A (en) | 1993-04-16 | 1995-06-06 | Baxter International Inc. | Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
US6123938A (en) | 1996-10-17 | 2000-09-26 | The Regents Of The University Of California | Human urinary hyaluronidase |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
AU2002220002B2 (en) | 2000-10-31 | 2006-12-14 | Evonik Corporation | Methods and compositions for enhanced delivery of bioactive molecules |
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
ES2602145T3 (es) | 2002-09-06 | 2017-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa |
PT2177620E (pt) | 2003-03-05 | 2015-02-16 | Halozyme Inc | Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem |
EP1687400A4 (en) | 2003-10-08 | 2009-01-07 | Wolf Wilson Mfg Corp | METHODS AND DEVICES FOR CELL CULTURE USING GAS PERMEABLE MATERIALS |
CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
AU2006328944B2 (en) | 2005-12-21 | 2011-08-25 | Sentoclone International Ab | Method for treating disseminated cancer |
WO2007071390A1 (en) | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating malignant melanoma |
WO2007071409A1 (en) | 2005-12-21 | 2007-06-28 | Sentoclone Ab | Method for treating colon cancer |
CA2645042A1 (en) | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
US7951365B2 (en) | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
US20150320798A1 (en) | 2012-11-27 | 2015-11-12 | The Johns Hopkins University | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
ES2385239B1 (es) | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
JP2014506116A (ja) | 2010-11-12 | 2014-03-13 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Il−2部分とポリマーとのコンジュゲート |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
EP2768939B1 (en) | 2011-10-21 | 2016-08-17 | Cell Medica Limited | Device for the aseptic expansion of cells |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
SG11201407226WA (en) | 2012-05-18 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
CN110241086A (zh) | 2012-06-11 | 2019-09-17 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
ES2862433T3 (es) | 2012-11-27 | 2021-10-07 | Ivan Marques Borrello | Uso de linfocitos infiltrantes de médula ósea alogénicos tratados con ciclofosfamida postrasplante para aumentar la inmunidad antitumoral |
CA2902448C (en) | 2013-03-01 | 2023-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
EP3821898A1 (en) | 2013-03-01 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
AU2014302589B2 (en) | 2013-06-24 | 2020-05-14 | Wilson Wolf Manufacturing, LLC | Closed system device and methods for gas permeable cell culture process |
WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
KR20230085225A (ko) | 2014-03-20 | 2023-06-13 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 입양 세포 요법을 위한 종양-침윤 림프구 |
US20170044496A1 (en) | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
CN106574244B (zh) * | 2014-06-11 | 2022-01-07 | 保利比奥斯博特有限责任公司 | 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗 |
KR20170067751A (ko) | 2014-09-04 | 2017-06-16 | 더 존스 홉킨스 유니버시티 | 저산소 및 정상산소 교대 조건에서 골수 침윤성 림프구의 활성화 |
CN107074932A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
CN107406837A (zh) | 2015-01-04 | 2017-11-28 | 波塔力克斯有限公司 | 修饰的dna酶及其用途 |
RU2020123735A (ru) | 2015-04-27 | 2020-07-30 | Кэнсэр Ресерч Текнолоджи Лимитед | Способ лечения рака |
CA2984234C (en) | 2015-05-01 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2017072251A1 (en) | 2015-10-28 | 2017-05-04 | Life Technologies As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
CA3068387A1 (en) | 2016-06-28 | 2018-01-04 | Geneius Biotechnology, Inc. | T cell compositions for immunotherapy |
CN106244538A (zh) | 2016-08-04 | 2016-12-21 | 英普乐孚生物技术(上海)有限公司 | 一种恶性腹水来源的til细胞的分离培养方法 |
WO2018081473A1 (en) | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI826360B (zh) | 2016-11-17 | 2023-12-21 | 美商艾歐凡斯生物治療公司 | 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法 |
WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
CN106591232A (zh) | 2017-01-04 | 2017-04-26 | 安徽安龙基因医学检验所有限公司 | 一种高效的pd‑1‑cd8+t细胞的培养方法 |
WO2018170188A2 (en) | 2017-03-14 | 2018-09-20 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
CN107384867B (zh) | 2017-08-04 | 2020-09-11 | 北京世纪劲得生物技术有限公司 | 一种肿瘤组织til细胞制备方法及专用培养基 |
-
2017
- 2017-11-17 TW TW106139868A patent/TWI826360B/zh active
- 2017-11-17 US US16/462,056 patent/US11401507B2/en active Active
- 2017-11-17 BR BR112019009925A patent/BR112019009925A2/pt unknown
- 2017-11-17 AU AU2017362418A patent/AU2017362418A1/en active Pending
- 2017-11-17 JP JP2019525747A patent/JP7125392B2/ja active Active
- 2017-11-17 WO PCT/US2017/062219 patent/WO2018094167A1/en unknown
- 2017-11-17 EP EP17817949.5A patent/EP3541930A1/en active Pending
- 2017-11-17 MX MX2019005617A patent/MX2019005617A/es unknown
- 2017-11-17 CN CN201780083537.0A patent/CN110199016A/zh active Pending
- 2017-11-17 MA MA046916A patent/MA46916A/fr unknown
- 2017-11-17 KR KR1020197016785A patent/KR102618948B1/ko active IP Right Grant
- 2017-11-17 CA CA3044250A patent/CA3044250A1/en active Pending
-
2019
- 2019-05-15 IL IL266655A patent/IL266655A/en unknown
-
2021
- 2021-01-05 US US17/141,454 patent/US11293009B2/en active Active
- 2021-02-19 US US17/180,200 patent/US11220670B2/en active Active
-
2022
- 2022-06-09 US US17/836,998 patent/US20230106186A1/en active Pending
- 2022-08-12 JP JP2022128638A patent/JP2022167931A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US11220670B2 (en) | 2022-01-11 |
AU2017362418A1 (en) | 2019-06-06 |
TWI826360B (zh) | 2023-12-21 |
MA46916A (fr) | 2019-09-25 |
US20190276802A1 (en) | 2019-09-12 |
IL266655A (en) | 2019-07-31 |
EP3541930A1 (en) | 2019-09-25 |
JP7125392B2 (ja) | 2022-08-24 |
KR102618948B1 (ko) | 2023-12-27 |
CA3044250A1 (en) | 2018-05-24 |
JP2022167931A (ja) | 2022-11-04 |
WO2018094167A1 (en) | 2018-05-24 |
MX2019005617A (es) | 2019-08-14 |
US20210123020A1 (en) | 2021-04-29 |
TW201831682A (zh) | 2018-09-01 |
US20210189339A1 (en) | 2021-06-24 |
US11401507B2 (en) | 2022-08-02 |
US20230106186A1 (en) | 2023-04-06 |
US11293009B2 (en) | 2022-04-05 |
KR20190084101A (ko) | 2019-07-15 |
CN110199016A (zh) | 2019-09-03 |
JP2019534030A (ja) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019009925A2 (pt) | método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . | |
BR112017016019A2 (pt) | método para tratamento de câncer, artigo para fabricação, e, kit. | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
MX2016012176A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
CO2019010698A2 (es) | Vacunas de peptidos | |
BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
MX2021006734A (es) | Metodo para tratar el cancer. | |
BR112014009276A8 (pt) | uso de inibidores de tirosina quinase de bruton (btk) | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
MX2019011148A (es) | Metodos de tratamiento. | |
PH12017500787A1 (en) | Methods of selecting t cell line and donor thereof for adoptive cellular therapy | |
BR112015006176A8 (pt) | método de tratamento de câncer em um indivíduo com necessidade de tratamento | |
MX2018002344A (es) | Metodo para tratar el cancer. | |
MX2017007256A (es) | Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer. | |
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
CL2018001108A1 (es) | Composiciones y métodos para transducción de tumores | |
MX2023006039A (es) | Celulas inmunes defectuosas para suv39h1. | |
UA111738C2 (uk) | Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин | |
BR112017012142A2 (pt) | método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama | |
MX2020001727A (es) | Terapia de combinacion. | |
BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
MX2019013862A (es) | Terapia de combinacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |